Abstract

Doximity, Inc. will release fiscal Q1 2026 results on August 06, 2026, Post Market; this preview outlines expected revenue growth, margin trajectory, EPS dynamics, and institutional viewpoints over the last six months.

Market Forecast

Consensus for the current quarter points to total revenue of 151.73 million US dollars, up 8.73% year over year, with estimated EBIT of 65.33 million and EPS of 0.31, implying a modest 1.25% EPS increase and a 6.83% EBIT decline year over year; management’s implied mix indicates stable, high gross margins and resilient net profitability. The company’s platform subscription remains the core driver with outsized mix, while product adoption and renewals are expected to sustain momentum; the subscriptions business is positioned as the most promising segment, with 608.41 million US dollars in trailing revenue contribution and a dominant mix share.

Last Quarter Review

Doximity, Inc. reported last quarter revenue of 145.37 million US dollars (up 5.12% year over year), gross profit margin of 86.65%, GAAP net profit attributable to shareholders of 19.11 million US dollars, net profit margin of 13.15%, and adjusted EPS of 0.26 (down 31.58% year over year). The company modestly exceeded revenue expectations and delivered slightly better-than-anticipated EBIT, while EPS trailed consensus as expense timing and mix effects weighed; subscriptions remained the main business driver with elevated contribution and steady expansion dynamics.

Main business highlights showed subscription revenue at 608.41 million US dollars on a trailing basis, contributing approximately 94.35% of mix, while other revenue contributed 36.45 million US dollars; the segment mix underscores the platform-led model’s consistency and the cross-sell opportunity within enterprise clients.

Current Quarter Outlook

Core Platform Subscriptions

The subscription engine remains the cornerstone of Doximity, Inc.’s quarterly profile, supported by enterprise renewals, usage elasticity around key engagement products, and stable dollar-based retention. Forecast revenue of 151.73 million US dollars and incremental EBIT of 65.33 million align with a pattern of high-80s gross margins and a disciplined operating expense cadence, which together support a 0.31 EPS estimate. A year-over-year revenue growth rate of 8.73% suggests healthier booking trends versus the prior quarter’s 5.12% growth, and points to improved selling conditions into health systems and life sciences customers. Investor focus will be on the pace of upsell across modules and whether elevated renewal cohorts continue to underpin retention above sector averages.

Most Promising Growth Vector: Subscriptions at Scale

Within the product suite, the scaled subscription base is the largest catalyst for upside surprise given its 608.41 million US dollars trailing revenue footprint and approximately 94% contribution to mix. Even modest improvements in net expansion rates and pricing capture can translate into outsized incremental margin, given gross margins at 86.65% last quarter and the relatively fixed nature of core platform costs. The near-term question for this quarter is how marketing and client engagement expenses balance against mix shift, as guidance embeds lower EBIT year-over-year despite revenue growth; if sales efficiency gains materialize, earnings leverage could outperform the 1.25% EPS growth assumption.

Key Stock Price Drivers This Quarter

Earnings sensitivity hinges on three variables: revenue outturn versus the 151.73 million US dollars estimate, gross margin quality, and expense timing’s impact on EBIT. An 8.73% revenue growth print, combined with gross margin tracking close to last quarter’s 86.65%, would argue for stable operating leverage; conversely, heavier selling and R&D investment could cap EBIT at the forecasted 65.33 million US dollars, reflecting a 6.83% year-over-year decline. Watch for commentary on pipeline linearity and renewal cadence, as small deviations in enterprise deal timing can move quarterly EPS around the 0.31 mark.

Analyst Opinions

Across recent institutional previews within the last six months, the prevailing stance leans constructive, with most commentary emphasizing the durability of high gross margins, consistent subscription renewals, and a supportive revenue trajectory near the high single digits. Positive views cite the combination of 8.73% revenue growth guidance and resilient profitability as adequate to defend valuation into the print, even as EBIT is forecast to decline year over year due to elevated operating investments. In this majority camp, analysts highlight that a high-80s gross margin profile provides cushion for incremental product investments while maintaining positive EPS growth and cash generation, framing risk-reward as favorable should execution on renewals and upsell remain intact.